The U.S. Department of Health and Human Services has published a new interim policy in the Federal Register that permits licensed pharmacies and physicians to compound six previously restricted peptides—BPC-157, TB-500, epitalon, KPV, MOTS-c and Semax—without Food and Drug Administration enforcement action, provided compounders meet requirements for ingredient quality, manufacturing standards, safety reporting, labeling and patient-specific prescriptions. The development, reported by Reuters on Oct. 28, marks a concrete regulatory shift for a peptide sector that has operated under significant restrictions.
According to the Reuters report by Sneha S K, with additional reporting by Kamal Choudhury and Siddhi Mahatole, the policy follows a July FDA advisory committee recommendation to allow compounding of the six peptides, despite agency scientists raising concerns about insufficient safety and effectiveness data. Health and Human Services officials said the approach could reduce reliance on potentially unsafe research-use-only peptides imported from foreign manufacturers while improving patient access. Industry representatives welcomed the decision, though critics warned of potential contamination, impurities and unknown side effects.
The measure is not an FDA approval of the peptides and could be reconsidered if safety or quality concerns emerge. Still, analysts estimate the peptide market could reach $2 billion to $3 billion if legitimized, giving the policy significant commercial weight. For Adaptogenics Health Corp., a company building a science-led portfolio of peptide and small molecule programs, the shift adds a new dimension to the market environment. Adaptogenics (CSE: ADPT) is evaluating opportunities in metabolic health, muscle preservation, mitochondrial biology and inflammation, and continues its existing nutraceutical operations while assessing GLP-1 companion products for challenges associated with medical weight loss.
The policy’s conditions—covering ingredient quality, manufacturing standards, safety reporting and labeling—mean compounders must invest in compliance infrastructure, potentially raising barriers for smaller operators while favoring established players. The interim nature of the policy also introduces uncertainty; a reversal could disrupt supply chains and patient access. The latest updates relating to ADPT are available through https://ibn.fm/ADPT.
The announcement was disseminated through BioMedWire, a communications platform focused on biotechnology and life sciences that is part of the Dynamic Brand Portfolio at IBN. For readers tracking regulatory risk in the peptide space, the policy signals that federal enforcement priorities are shifting, but the absence of formal approval and the possibility of reconsideration mean safety data and quality controls will remain central to the sector’s credibility.
